Physician
Springfield Hospital
Springfield Hospital was paid $963K by Medicaid between Jan 2018 and Nov 2024, across 48 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoSPRINGFIELD HOSPITAL
SPRINGFIELD, VT 05156
SPRINGFIELD, VT 05156
33aNPI1033225875assigned 08/22/2006
33bProvider typeEmergency Medicine Physician
28Total paid$963K
24GClaims32,393
24DCodes billed48
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Vermont
Rank by total paid#2 of 10
Median peer was paid$45K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,275 | $347K | |
| 2019 | 5,709 | $196K | |
| 2020 | 3,644 | $86K | |
| 2021 | 6,438 | $203K | |
| 2022 | 3,268 | $75K | |
| 2023 | 2,560 | $29K | |
| 2024incomplete | 2,499 | $28K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 3,391 | 2,675 | $237K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 3,153 | 1,677 | $234K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 2,881 | 1,934 | $216K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.5% | 4,613 | 3,278 | $43K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.7% | 815 | 590 | $35K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.5% | 318 | 177 | $33K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 324 | 210 | $31K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.0% | 1,776 | 1,182 | $20K |
| 80053 | Comprehensive metabolic panel | 1.8% | 3,276 | 2,064 | $17K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 512 | 266 | $13K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 3,893 | 2,463 | $13K |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 2,015 | 1,366 | $12K |
36 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 261 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 100 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 156 | $7K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 389 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 204 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 726 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 744 | $4K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 41 | $3K |
| 11721 | <1% | 301 | $2K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 182 | $2K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 14 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 81 | $1K |
| 83735 | <1% | 337 | $1K | |
| 80061 | Lipid panel | <1% | 127 | $1K |
| 84484 | <1% | 217 | $864.15 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 45 | $797.75 |
| 87899 | <1% | 72 | $552.22 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 276 | $484.54 |
| 83605 | <1% | 92 | $439.57 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 130 | $379.38 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 103 | $339.22 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $246.29 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15 | $246.29 |
| 86140 | <1% | 89 | $208.58 | |
| 69210 | <1% | 20 | $172.81 | |
| 81000 | <1% | 137 | $169.32 | |
| 81001 | <1% | 145 | $153.21 | |
| 81002 | <1% | 78 | $96.20 | |
| 87070 | <1% | 16 | $71.36 | |
| 81003 | <1% | 128 | $63.77 | |
| 87081 | <1% | 13 | $63.24 | |
| 99459 | <1% | 84 | $27.62 | |
| 94761 | <1% | 44 | $21.20 | |
| 85652 | <1% | 14 | $20.12 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17 | $3.00 |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWESCOTT, KAYDA (CHIEF FINANCIAL OFFICER)